Aeterna Zentaris Stock News

Aeterna Zentaris Inc. (AEZS) with the stream of 0.00% also noticed, India RiceBran Technologies (RIBT) encountered a rapid change of -3.02% in the last hour of trading session. Aeterna Zentaris The post Captivating Stock: Aeterna Zentaris Inc. (NASDAQ:AEZS), RiceBran Technologies (NASDAQ:RIBT) appeared first on Stocks Equity .

Aeterna Zentaris Inc. (NASDAQ:AEZS) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 4.66% to the previous days close as strong demand from buyers drove the stock to $0.49. Actively observing the price movement in the last trading, the stock closed the session at $0.47, falling within a range of $0.4406 The Aeterna Zentaris Inc. (NASDAQ: AEZS) Metrics You Need To Know Right Now Read More »

The trading price of Aeterna Zentaris Inc. (NASDAQ:AEZS) closed lower on Monday, November 22, closing at $0.48, -5.67% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Aeterna Zentaris Inc. (NASDAQ:AEZS) price closed lower on Monday, November 15, dropping -1.14% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

A few hot penny stocks are seeing major movement on Friday as shares ride higher and we've got all the details traders need. The post 3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains To

CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a divers

CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commerci

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

– Dr. Levy is a well-established n euroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders

CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commerci

- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of m acimorelin for th

Aeterna Zentaris Inc (NASDAQ: AEZS) has commenced its pivotal Phase 3 DETECT trial evaluating macimorelin as a diagnosis of childhood-onset growth hormone deficiency (CGHD). The investigational n

– Safety and efficacy study for macimorelin initiated as agreed with U . S . FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP")

– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET